Transcenta Anti-sclerostin Monoclonal Antibody TST002 (Blosozumab) Received Approval from China CDE to Initiate Phase II Clinical Trial in Patients with Reduced Bone Mineral Density
Transcenta Holding Limited announces that it has received approval from China Center for Drug Evaluation to initiate Phase II clinical trial of TST002.
